SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Jonathan Weiss/Shutterstock
Business
Ease of Use, Higher Efficacy Drive Lilly’s New Diabetes Treatments
Diabetes and obesity remain a problem, even during a pandemic. Eli Lilly is continuing to develop the 13 diabetes drugs it has in Phase I through Phase III trials, with data from various trials planned for release throughout the coming year.
May 20, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Immunai Founders Discuss Plan to Map the Entire Immune System
With its proprietary, top-down view of the immune system and purportedly the world’s largest proprietary data devoted to clinical immunologics, it aims to catalyze significant improvements in disease detection, diagnosis and treatment.
May 19, 2020
 · 
4 min read
 · 
Gail Dutton
Business
CDC to Launch Massive Population-based Antibody Testing for SARS-CoV-2
Expected to launch in June or July, the study plans to test as many as 325,000 people to learn how the SARS-CoV-2 virus is spreading nationally, according to Reuters, reporting before the official announcement.
May 19, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Frost & Sullivan Predicts Telemedicine Surge Will Continue After Pandemic Ends
U.S. demand for telehealth will soar by 64.3% in 2020 because of the COVID-19 pandemic, according to a report released by Frost & Sullivan.
May 18, 2020
 · 
5 min read
 · 
Gail Dutton
Tablet with the diagnosis parkinson's disease on the display
Business
Pandemic Delays Neurocrine’s Drug Launch for Parkinson’s Disease
With the COVID-19 pandemic closing physicians’ offices and causing patients to think twice about exposing themselves in healthcare settings, Neurocrine is delaying its launch of Ongentysis®.
May 15, 2020
 · 
4 min read
 · 
Gail Dutton
Business
“Game-Changing” Gene Therapy a Joint Effort by Urologist Consortium and FKD Therapies
A gene therapy that eliminates the need for radical cystectomies (complete removal of the bladder) in a particular, aggressive form of bladder cancer is undergoing Priority Review by the U.S. Food and Drug Administration.
May 14, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Icosavax’s Nanoparticle VLP-based Vaccine Offers First-in-Class Solution for RSV
“VLPs have special immunological properties and are processed differently by the immune system so they have longer duration,” Adam Simpson, CEO of Icosavax, told BioSpace.
May 13, 2020
 · 
4 min read
 · 
Gail Dutton
Business
NSF-funded Smartphone COVID-19 Diagnostic Test Could Put Testing in the Hands of the Public
A smartphone diagnostic test for COVID-19 being developed by a University of Utah researcher holds the potential for quick, accurate testing without the need for individuals to go to a healthcare facility. A prototype may be ready within two to three months.
May 11, 2020
 · 
4 min read
 · 
Gail Dutton
Business
AMO Drug May Restore Normal Learning Function in Some Genetic Brain Diseases
AMO Pharma, a British biopharmaceutical company, is targeting a pathway most often associated with cancer to treat people with genetic encephalopathy.
May 8, 2020
 · 
4 min read
 · 
Gail Dutton
Business
Multiple Studies Suggest COVID-19 Mortality Rate May Be Lower Than Expected
The actual death toll for COVID-19 won’t be calculable for some time, but there are early indications that it may be significantly lower than calculations of deaths per confirmed cases lead one to believe.
May 7, 2020
 · 
5 min read
 · 
Gail Dutton
lucarista/Shutterstock
FDA
Tabrecta: FDA Gives Novartis Approval for First-Ever Therapy for NSCLC Tumors with METex14
Developed by Novartis, the drug, Tabrecta, is designed for a type of NSCLC that has spread to other parts of the body and cannot be removed by surgery.
May 6, 2020
 · 
4 min read
 · 
Gail Dutton
Business
MilliporeSigma CEO Udit Batra Shares His Secrets for Career Success
In 1996, Udit Batra received his Ph.D. in chemical engineering from Princeton University. 24 years later, he heads a MilliporeSigma, $7.5 billion global life sciences company with a catalog of some 300,000 items used by life sciences researchers and developers throughout the world.
May 5, 2020
 · 
4 min read
 · 
Gail Dutton
Lone Star Bio
Luminex Returns to Profitability, Thanks – Partially – to COVID-19
Luminex, a developer of molecular diagnostics and clinical tools for the life sciences industry, returned to profit this quarter – well ahead of schedule – after a major client, LabCorp, departed in 2019.
May 5, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
Biotech Professionals Express Fears…and Hope, During Pandemic
While the biopharmaceutical industry is working frantically to develop the tests, vaccines and therapeutics to combat COVID-19, the people doing the work are pushing their fears to one side. But, when asked, they admit to concerns. Not suprisingly, they mirror the fears shared by much of the world.
May 1, 2020
 · 
5 min read
 · 
Gail Dutton
Genetown
Geneius Develops Off-the-Shelf T Cell Therapy Targeting SARS-CoV-2
The assumption is that by increasing the number of antigen-specific T cells in the body, the patient’s immune system can overwhelm the SARS-CoV-2 virus, halting the disease.
May 1, 2020
 · 
4 min read
 · 
Gail Dutton
Load More